{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-048285","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.468491+00:00","generated_at":"2026-05-29T12:15:40.319401+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Telomir-1 reverses insulin resistance to near pre-diabetes in zebrafish T2D study","bullets":["Telomir-1 restored glucose homeostasis, reducing HOMA-IR values and improving oral glucose tolerance in zebrafish model.","Dose-dependent normalization of blood glucose levels observed; insulin resistance reversed to near pre-diabetes levels.","Novel mechanism targets iron metabolism to address oxidative stress and beta-cell damage, root causes of Type 2 diabetes.","Treated models showed increased survival rates, reinforcing therapeutic potential of Telomir-1."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-048285","json":"https://secwatch.observer/filing/0001493152-24-048285.json","markdown":"https://secwatch.observer/filing/0001493152-24-048285.md","text":"https://secwatch.observer/filing/0001493152-24-048285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224048285/0001493152-24-048285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224048285/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T12:15:40.319401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}